<i>CEBPA</i> mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
Franziska Taube(University Hospital Carl Gustav Carus), Christian Thiede(University Hospital Carl Gustav Carus), Michael Krämer(University Hospital Carl Gustav Carus), Sebastian Stasik, Hermann Einsele(Universitätsklinikum Würzburg), Gerhard Ehninger(University Hospital Carl Gustav Carus), Markus Schaich(Rems-Murr-Klinikum), Utz Krug(Klinikum Leverkusen), Sebastian Scholl(Jena University Hospital), Wolfgang E. Berdel(University Hospital Münster), Björn Steffen(Goethe University Frankfurt), Christoph Röllig(University Hospital Carl Gustav Carus), Martin Bornhäuser(Technische Universität Dresden), Carsten Müller‐Tidow(Heidelberg University), Claudia D. Baldus(University Hospital Schleswig-Holstein), Andreas Hochhaus(Jena University Hospital), Jan Moritz Middeke(Fresenius (Germany)), Tim H. Brümmendorf(National University Cancer Institute, Singapore), A. Petzold(Center for Systems Biology Dresden), Andreas Neubauer(RWTH Aachen University), Friedrich Stölzel(German Cancer Research Center), Mathias Hänel(Klinikum Chemnitz), Christoph Schliemann(University Hospital Münster), Andreas Burchert(Philipps University of Marburg), Ulrich Kaiser(University of Applied Sciences Landshut), Peter J.M. Valk(Erasmus MC Cancer Institute), Katja Sockel(Innsbruck Medical University), Roger Mulet‐Lazaro(Oncode Institute), Uwe Platzbecker(National Center for Tumor Diseases), Stefan W. Krause(Universitätsklinikum Erlangen), Richard Noppeney(Essen University Hospital), Hubert Serve(Goethe University Frankfurt), Martin Kaufmann(Robert Bosch Hospital), Malte von Bonin(Städtisches Klinikum Dresden), Julia Annabell Georgi(University Hospital Carl Gustav Carus), Kerstin Schäfer‐Eckart(Nuremberg Hospital), Sylvia Herold(University Hospital Carl Gustav Carus), Ralph Naumann(University of Siegen), Johannes Schetelig(University Hospital Carl Gustav Carus), Alwin Krämer(Heidelberg University)
Cited by 170
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k